Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Overall MarketRank^™

1.70 out of 5 stars

Medical Sector

264th out of 2,041 stocks

Biotechnology Industry

23rd out of 157 stocks

3.5 Analyst's Opinion

Consensus Rating
Gemini Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.00, Gemini Therapeutics has a forecasted upside of 83.3% from its current price of $12.00.
Amount of Analyst Coverage
Gemini Therapeutics has only been the subject of 4 research reports in the past 90 days.

5.0 Community Rank

Outperform Votes
Gemini Therapeutics has received 6 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Gemini Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Gemini Therapeutics has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Gemini Therapeutics and other stocks. Vote “Outperform” if you believe GMTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GMTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Gemini Therapeutics does not currently pay a dividend.
Dividend Growth
Gemini Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gemini Therapeutics insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Gemini Therapeutics (NASDAQ:GMTX) Frequently Asked Questions

Is Gemini Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gemini Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Gemini Therapeutics stock.
View analyst ratings for Gemini Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Gemini Therapeutics?

Wall Street analysts have given Gemini Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gemini Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for GMTX?

4 brokers have issued 1 year price targets for Gemini Therapeutics' stock. Their forecasts range from $20.00 to $25.00. On average, they expect Gemini Therapeutics' share price to reach $22.00 in the next twelve months. This suggests a possible upside of 83.3% from the stock's current price.
View analysts' price targets for Gemini Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Gemini Therapeutics' key executives?

Gemini Therapeutics' management team includes the following people:

Mr. Jason Patrick Meyenburg M.B.A., M.D., CEO, Pres & Director (Age 44, Pay $530.29k)
Dr. Scott Lauder Ph.D., Chief Technology Officer (Age 57, Pay $480.3k)
Dr. Marc E. Uknis F.A.C.S., M.D., Chief Medical Officer (Age 56, Pay $397.39k)
Mr. Brian Piekos, CFO & Principal Accounting and Financial Officer (Age 46)
Dr. Walter Strapps, Chief Scientific Officer
Ms. Precillia Redmond, Chief People Officer

Who are some of Gemini Therapeutics' key competitors?

Some companies that are related to Gemini Therapeutics include ImmunityBio (IBRX), Immunocore (IMCR), BioAtla (BCAB), Edgewise Therapeutics (EWTX), Cullinan Oncology (CGEM), Concordia International (CXR), Nurix Therapeutics (NRIX), Trillium Therapeutics (TRIL), PureTech Health (PRTC), Kinnate Biopharma (KNTE), Stem (STEM), Silverback Therapeutics (SBTX), Connect Biopharma (CNTB), 4D Molecular Therapeutics (FDMT) and Vor Biopharma (VOR).
View all of GMTX's competitors.

What is Gemini Therapeutics' stock symbol?

Gemini Therapeutics trades on the NASDAQ under the ticker symbol "GMTX."

Who are Gemini Therapeutics' major shareholders?

Gemini Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Altium Capital Management LP (0.47%).

Which major investors are buying Gemini Therapeutics stock?

GMTX stock was bought by a variety of institutional investors in the last quarter, including Altium Capital Management LP.

How do I buy shares of Gemini Therapeutics?

Shares of GMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gemini Therapeutics' stock price today?

One share of GMTX stock can currently be purchased for approximately $12.00.

How much money does Gemini Therapeutics make?

Gemini Therapeutics has a market capitalization of $515.99 million.

How many employees does Gemini Therapeutics have?

Gemini Therapeutics employs 29 workers across the globe.

What is Gemini Therapeutics' official website?

The official website for Gemini Therapeutics is www.geminitherapeutics.com.

How can I contact Gemini Therapeutics?

The company can be reached via phone at 617 678 3113.

This page was last updated on 5/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Gemini Therapeutics Stock Forecast, Price & News

Adding

Adding

Adding Gemini Therapeutics, Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Headlines

About Gemini Therapeutics

MarketRank™

Overall MarketRank™

3.5 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage

5.0 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment